The Oncologist-Patient Partnership

If there is ever an annual follow up CT scan that does not cause me significant anxiety, this year will be the one.

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert oncologists.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.

Dr. Suresh Ramalingam discusses how Tagrisso has ushered in a new era of care for patients with advanced EGFR+ non-small cell lung cancer.